ArticleCancers2022

Tumor Response, Disease Control, and Progression-Free Survival as Surrogate Endpoints in Trials Evaluating Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Study- and Patient-Level Analyses.

Nobuyuki HoritaPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.